263 related articles for article (PubMed ID: 25601964)
41. Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Curtit E; Nouyrigat P; Dohollou N; Levy E; Lortholary A; Gligorov J; Facchini T; Jaubert D; Maille N; Pivot X; Grangé V; Cals L
Eur J Cancer; 2011 Nov; 47(16):2396-402. PubMed ID: 21920729
[TBL] [Abstract][Full Text] [Related]
42. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
43. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
[TBL] [Abstract][Full Text] [Related]
44. Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.
Floquet A; Doussau A; Brouste V; Cany L; Dutin JP; Mathoulin-Pélissier S
Cancer Chemother Pharmacol; 2014 Jan; 73(1):61-8. PubMed ID: 24141374
[TBL] [Abstract][Full Text] [Related]
45. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
46. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
[TBL] [Abstract][Full Text] [Related]
47. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
[TBL] [Abstract][Full Text] [Related]
48. A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.
Cheng M; Song Z; Qi Y; Wang X; Zhang L; Shi J; Wang M
Oncol Res Treat; 2019; 42(5):269-274. PubMed ID: 30943501
[TBL] [Abstract][Full Text] [Related]
49. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors.
Iqbal S; Tsao-Wei DD; Quinn DI; Gitlitz BJ; Groshen S; Aparicio A; Lenz HJ; El-Khoueiry A; Pinski J; Garcia AA
Am J Clin Oncol; 2011 Feb; 34(1):27-31. PubMed ID: 20142723
[TBL] [Abstract][Full Text] [Related]
50. Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
Magné N; Castadot P; Chargari C; Di Leo A; Philippson C; Van Houtte P
Radiother Oncol; 2009 Jan; 90(1):116-21. PubMed ID: 19013659
[TBL] [Abstract][Full Text] [Related]
51. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
Fracasso PM; Rodriguez LC; Herzog TJ; Fears CL; Goodner SA; Govindan R; Picus J; Rader JS; Tan BR; Arquette MA
Cancer; 2003 Aug; 98(3):610-7. PubMed ID: 12879480
[TBL] [Abstract][Full Text] [Related]
52. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Misset JL; Dieras V; Gruia G; Bourgeois H; Cvitkovic E; Kalla S; Bozec L; Beuzeboc P; Jasmin C; Aussel JP; Riva A; Azli N; Pouillart P
Ann Oncol; 1999 May; 10(5):553-60. PubMed ID: 10416005
[TBL] [Abstract][Full Text] [Related]
53. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
54. Phase II study of dose-dense doxorubicin and docetaxel as neoadjunvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer.
García-Mata J; García-Palomo A; Calvo L; Mel R; Cruz JJ; Ramos M
Clin Transl Oncol; 2008 Nov; 10(11):739-44. PubMed ID: 19015070
[TBL] [Abstract][Full Text] [Related]
55. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer.
Alexopoulos A; Karamouzis MV; Stavrinides H; Ardavanis A; Kandilis K; Stavrakakis J; Georganta C; Rigatos G
Ann Oncol; 2004 Jun; 15(6):891-5. PubMed ID: 15151945
[TBL] [Abstract][Full Text] [Related]
56. A feasibility study of neo-adjuvant low-dose fractionated radiotherapy with two different concurrent anthracycline-docetaxel schedules in stage IIA/B-IIIA breast cancer.
Nardone L; Valentini V; Marino L; De Santis MC; Terribile D; Franceschini G; Balducci M; Mantini G; Mattiucci G; Mulè A; Belli P; Masetti R
Tumori; 2012; 98(1):79-85. PubMed ID: 22495705
[TBL] [Abstract][Full Text] [Related]
57. Phase I trial of liposomal encapsulated doxorubicin (Myocet; D-99) and weekly docetaxel in advanced breast cancer patients.
Mrózek E; Rhoades CA; Allen J; Hade EM; Shapiro CL
Ann Oncol; 2005 Jul; 16(7):1087-93. PubMed ID: 15849219
[TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer.
Malhotra V; Dorr VJ; Lyss AP; Anderson CM; Westgate S; Reynolds M; Barrett B; Perry MC
Clin Breast Cancer; 2004 Dec; 5(5):377-84. PubMed ID: 15585077
[TBL] [Abstract][Full Text] [Related]
59. Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Wesolowski R; Peereboom D; Weiss P; Elson P; Thomas Budd G
Invest New Drugs; 2010 Aug; 28(4):502-8. PubMed ID: 19434371
[TBL] [Abstract][Full Text] [Related]
60. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
Androulakis N; Kouroussis C; Mavroudis D; Kakolyris S; Souglakos J; Agelaki S; Kalbakis K; Malas K; Pallis A; Samonis G; Georgoulias V
Eur J Cancer; 2002 Oct; 38(15):1992-7. PubMed ID: 12376203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]